Details

Autor(en) / Beteiligte

• XIANGLAN YAO
• FREDRIKSSON, Karin
• LEVINE, Stewart J
• YU, Zu-Xi
• XIULI XU
• RAGHAVACHARI, Nalini
• KEERAN, Karen J
• ZYWICKE, Gayle J
• KWAK, Minjung
• AMAR, Marcelo J. A
• REMALEY, Alan T

Titel

Apolipoprotein E Negatively Regulates House Dust Mite-induced Asthma via a Low-Density Lipoprotein Receptor-mediated Pathway

Ist Teil von

• American journal of respiratory and critical care medicine, 2010-11, Vol.182 (10), p.1228-1238

Ort / Verlag

New York, NY: American Thoracic Society

Erscheinungsjahr

2010

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Distinct sets of corticosteroid-unresponsive genes modulate disease severity in asthma. To identify corticosteroid-unresponsive genes that provide new insights into disease pathogenesis and asthma therapeutics. Experimental murine asthma was induced by nasal administration of house dust mite for 5 days per week. Dexamethasone and apolipoprotein E (apo E) mimetic peptides were administered via osmotic minipumps. Genome-wide expression profiling of the lung transcriptome in a house dust mite-induced model of murine asthma identified increases in apo E mRNA levels that persisted despite corticosteroid treatment. House dust mite-challenged apo E⁻(/)⁻ mice displayed enhanced airway hyperreactivity and goblet cell hyperplasia, which could be rescued by administration of an apo E(130-149) mimetic peptide. Administration of the apo E(130-149) mimetic peptide to house dust mite-challenged apo E⁻(/)⁻ mice also inhibited eosinophilic airway inflammation, IgE production, and the expression of Th2 and Th17 cytokines. House dust mite-challenged low-density lipoprotein receptor (LDLR) knockout mice displayed a similar phenotype as apo E⁻(/)⁻ mice with enhanced airway hyperreactivity, goblet cell hyperplasia, and mucin gene expression, but could not be rescued by the apo E(130-149) mimetic peptide, consistent with a LDLR-dependent mechanism. These findings for the first time identify an apo E-LDLR pathway as an endogenous negative regulator of airway hyperreactivity and goblet cell hyperplasia in asthma. Furthermore, our results demonstrate that strategies that activate the apo E-LDLR pathway, such as apo E mimetic peptides, might be developed into a novel treatment approach for patients with asthma.